Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gordon

Showing results (901-910 of 1,032) with videos related to

Pageof 104
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2013
Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiotaPurna C Kashyap, Angela Marcobal, Luke K Ursell, et al.
Molecular Cancer Therapeutics|June 18, 2020
A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) InhibitionEkaterina A Lesovaya, Alena V Savinkova, Olga V Morozova, et al.
Science (New York, N.Y.)|August 5, 2017
<i>Lactobacillus reuteri</i> induces gut intraepithelial CD4<sup>+</sup>CD8αα<sup>+</sup> T cellsLuisa Cervantes-Barragan, Jiani N Chai, Ma Diarey Tianero, et al.
Elife|December 13, 2017
Evolutionary transitions between beneficial and phytopathogenic <i>Rhodococcus</i> challenge disease managementElizabeth A Savory, Skylar L Fuller, Alexandra J Weisberg, et al.
Journal of Medicinal Chemistry|August 1, 1997
Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activityB Devadas, S K Freeman, M E Zupec, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Science Translational Medicine|November 25, 2016
Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutritionVitas E Wagner, Neelendu Dey, Janaki Guruge, et al.
Cancer|December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes projectBouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
Nature Microbiology|July 16, 2025
Integrative genomic reconstruction reveals heterogeneity in carbohydrate utilization across human gut bifidobacteriaAleksandr A Arzamasov, Dmitry A Rodionov, Matthew C Hibberd, et al.
Pageof 104

Showing results (901-910 of 1,032) with videos related to

Sort By:
Pageof 104
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2013
Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiotaPurna C Kashyap, Angela Marcobal, Luke K Ursell, et al.
Molecular Cancer Therapeutics|June 18, 2020
A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) InhibitionEkaterina A Lesovaya, Alena V Savinkova, Olga V Morozova, et al.
Science (New York, N.Y.)|August 5, 2017
<i>Lactobacillus reuteri</i> induces gut intraepithelial CD4<sup>+</sup>CD8αα<sup>+</sup> T cellsLuisa Cervantes-Barragan, Jiani N Chai, Ma Diarey Tianero, et al.
Elife|December 13, 2017
Evolutionary transitions between beneficial and phytopathogenic <i>Rhodococcus</i> challenge disease managementElizabeth A Savory, Skylar L Fuller, Alexandra J Weisberg, et al.
Journal of Medicinal Chemistry|August 1, 1997
Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activityB Devadas, S K Freeman, M E Zupec, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Science Translational Medicine|November 25, 2016
Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutritionVitas E Wagner, Neelendu Dey, Janaki Guruge, et al.
Cancer|December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes projectBouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
Nature Microbiology|July 16, 2025
Integrative genomic reconstruction reveals heterogeneity in carbohydrate utilization across human gut bifidobacteriaAleksandr A Arzamasov, Dmitry A Rodionov, Matthew C Hibberd, et al.
Pageof 104